FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3161739936> ?p ?o ?g. }

• W3161739936 abstract "Abstract Funding Acknowledgements Type of funding sources: None. Background Cardiac rehabilitation (CR) programs provide an opportunity to measure low density lipoprotein cholesterol (LDL-C) levels and optimise lipid lowering therapy (LLT) accordingly. New ESC guidelines released in August 2019 recommend lower absolute LDL-C target levels and an &gt;50% reduction from baseline in those at the highest risk. Purpose This study investigated the proportion of those patients who finished CR in 2019 that reached both their absolute and relative reduction in LDL-C levels, before and after the introduction of these new guidelines. We also analysed the choice and appropriateness of LLT. Methods A retrospective chart review of 163 patients who completed CR in 2019. A database was created containing baseline patient characteristics and LDL-C levels both prior and post CR; as well as the patient’s contemporary LLT. Those patients who did not have a previous diagnosis of atherosclerotic cardiovascular disease (ASCVD) were risk stratified as per ESC guidance. Baseline LDL-C levels were recorded, where possible, and otherwise calculated using pre-CR LDL profile with an adjustment made based on the projected effects of their LLT. Results Mean (SD) patient age was 62 (10) years, 123/163 (75%) were male and 142 (87%) patients had established ASCVD. 90/142 (63%) of very high-risk patients were treated with a high intensity LLT and 5/163 overall (3%) were prescribed ezetimibe. Overall, 96/163 (59%) patients in 2019 met their absolute LDL-C targets; 62% of applicable patients achieved an &gt;50% reduction in LDL-C levels. 104 (64%) of patients were treated in compliance with their contemporary guidelines. Both pre (n = 112) and post (n = 51) September 2019 cohorts were well matched. Fewer patients who were treated under the August 2019 guidelines reached their absolute LDL-C (51% v 63%, p &lt; 0.005) targets; achieved a &gt;50% reduction in LDL-C from baseline (48% vs 61%, p &lt; 0.005), or were compliant with the guidelines for their risk category (43% vs 73%, p &lt; 0.005). Conclusions Both high intensity statin therapy and ezetimibe are under-prescribed. Fewer patients are meeting the lower absolute LDL-C targets set out in the 2019 ESC guidelines. For those at high risk, determining the reduction in LDL-C from baseline reveals that even those meeting their absolute LDL-C targets may still be undertreated. LDL-C Target Achievement N Mean LDL Pre-CR (95% CI) Mean LDL-C Post CR (95% CI) Absolute LDL-C Target Met (%) Mean % LDL-C Reduction from Baseline (95% CI) &gt; 50% Reduction (% of applicable patients) Guidelines Achieved Pre-Sept20 112 2.7 (2.46-2.93) 1.64 (1.49- 1.79) 70 (63) 61 (56-66) 50 (65) 82 (73) Post Sept 20 51 2.83 (2.41-3.25) 1.83 (1.41-2.25) 26 (51) 48 (37-59) 11 (34) 22 (43) Total 163 2.72 (2.52- 2.91) 1.69 (1.57-1.82) 96 (59) 57 (52- 62) 61 (52) 104 (64 LDL-C targets met, stratified by contemporary guidelines followed. Abstract Figure. Choice of lipid lowering therapy in 2019" @default.
• W3161739936 created "2021-05-24" @default.
• W3161739936 creator A5011343003 @default.
• W3161739936 creator A5019694324 @default.
• W3161739936 creator A5020761186 @default.
• W3161739936 creator A5050349122 @default.
• W3161739936 creator A5059600205 @default.
• W3161739936 date "2021-05-01" @default.
• W3161739936 modified "2023-10-16" @default.
• W3161739936 title "Dyslipidaemia management in the cardiac rehabilitation clinic of a tertiary referral centre; analysis of the impact of new ESC guidance on LDL-C target achievement" @default.
• W3161739936 doi "https://doi.org/10.1093/eurjpc/zwab061.280" @default.
• W3161739936 hasPublicationYear "2021" @default.
• W3161739936 type Work @default.
• W3161739936 sameAs 3161739936 @default.
• W3161739936 citedByCount "0" @default.
• W3161739936 crossrefType "journal-article" @default.
• W3161739936 hasAuthorship W3161739936A5011343003 @default.
• W3161739936 hasAuthorship W3161739936A5019694324 @default.
• W3161739936 hasAuthorship W3161739936A5020761186 @default.
• W3161739936 hasAuthorship W3161739936A5050349122 @default.
• W3161739936 hasAuthorship W3161739936A5059600205 @default.
• W3161739936 hasConcept C126322002 @default.
• W3161739936 hasConcept C164705383 @default.
• W3161739936 hasConcept C2776135927 @default.
• W3161739936 hasConcept C2778163477 @default.
• W3161739936 hasConcept C2778657065 @default.
• W3161739936 hasConcept C2910763605 @default.
• W3161739936 hasConcept C512399662 @default.
• W3161739936 hasConcept C71924100 @default.
• W3161739936 hasConceptScore W3161739936C126322002 @default.
• W3161739936 hasConceptScore W3161739936C164705383 @default.
• W3161739936 hasConceptScore W3161739936C2776135927 @default.
• W3161739936 hasConceptScore W3161739936C2778163477 @default.
• W3161739936 hasConceptScore W3161739936C2778657065 @default.
• W3161739936 hasConceptScore W3161739936C2910763605 @default.
• W3161739936 hasConceptScore W3161739936C512399662 @default.
• W3161739936 hasConceptScore W3161739936C71924100 @default.
• W3161739936 hasLocation W31617399361 @default.
• W3161739936 hasOpenAccess W3161739936 @default.
• W3161739936 hasPrimaryLocation W31617399361 @default.
• W3161739936 hasRelatedWork W12370155 @default.
• W3161739936 hasRelatedWork W12931938 @default.
• W3161739936 hasRelatedWork W13547904 @default.
• W3161739936 hasRelatedWork W14300358 @default.
• W3161739936 hasRelatedWork W17451682 @default.
• W3161739936 hasRelatedWork W17780568 @default.
• W3161739936 hasRelatedWork W436439 @default.
• W3161739936 hasRelatedWork W64262 @default.
• W3161739936 hasRelatedWork W7417643 @default.
• W3161739936 hasRelatedWork W9399722 @default.
• W3161739936 isParatext "false" @default.
• W3161739936 isRetracted "false" @default.
• W3161739936 magId "3161739936" @default.
• W3161739936 workType "article" @default.